Literature DB >> 12379623

Protection against tuberculosis: cytokines, T cells, and macrophages.

S H E Kaufmann1.   

Abstract

Tuberculosis remains a major health problem, with two million deaths and eight million new cases annually. At the same time, two billion people (one third of the total world population) are infected with the aetiological agent, Mycobacterium tuberculosis. Of these, fewer than 10% ever develop disease, although the pathogen is not eradicated but rather contained in discrete lesions. Hence, the immune system is highly effective in containing the pathogen, but fails to eradicate it. Disease typically develops through reactivation once the immune system is weakened. The immune response to M tuberculosis is T cell dependent. It comprises not only the conventional CD4 and CD8 T cells, but also gammadelta T cells and CD1 restricted T cells. gammadelta T cells recognise phospholigands and no presentation molecules are known thus far. CD1 restricted T cells recognise glycolipids, which are highly abundant components of the mycobacterial cell wall. Although different T cells are required for optimum protection, the immune mechanisms known to have a role in acquired resistance can be associated with two major mechanisms: (a) activation of macrophages by cytokines; (b) direct cytolytic activity. In vivo granuloma formation, which is central to protection, is induced and sustained by cytokines. Mycobacteria are contained within granulomas and in this way are prevented from spreading all over the body.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379623      PMCID: PMC1766701          DOI: 10.1136/ard.61.suppl_2.ii54

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  7 in total

1.  Is the development of a new tuberculosis vaccine possible?

Authors:  S H Kaufmann
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 2.  How can immunology contribute to the control of tuberculosis?

Authors:  S H Kaufmann
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

3.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

4.  Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology.

Authors:  V P Mohan; C A Scanga; K Yu; H M Scott; K E Tanaka; E Tsang; M M Tsai; J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

Review 6.  Role of cytokines in tuberculosis.

Authors:  I E Flesch; S H Kaufmann
Journal:  Immunobiology       Date:  1993-11       Impact factor: 3.144

7.  Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection.

Authors:  D R Roach; H Briscoe; B Saunders; M P France; S Riminton; W J Britton
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

  7 in total
  65 in total

1.  Analysis of Dominant HIV Quasispecies Suggests Independent Viral Evolution Within Spinal Granulomas Coinfected with Mycobacterium tuberculosis and HIV-1 Subtype C.

Authors:  Sivapragashini Danaviah; Tulio de Oliveira; Michelle Gordon; Shunmugam Govender; Paul Chelule; Sureshnee Pillay; Thajasvarie Naicker; Sharon Cassol; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-17       Impact factor: 2.205

2.  Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection.

Authors:  Alexey Popov; Zeinab Abdullah; Claudia Wickenhauser; Tomo Saric; Julia Driesen; Franz-Georg Hanisch; Eugen Domann; Emma Lloyd Raven; Oliver Dehus; Corinna Hermann; Daniela Eggle; Svenja Debey; Trinad Chakraborty; Martin Krönke; Olaf Utermöhlen; Joachim L Schultze
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

3.  Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects.

Authors:  C Nilsson; S Aboud; K Karlén; B Hejdeman; W Urassa; G Biberfeld
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

4.  Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response.

Authors:  M Lichtner; R Rossi; F Mengoni; S Vignoli; B Colacchia; A P Massetti; I Kamga; A Hosmalin; V Vullo; C M Mastroianni
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  Interaction of CarD with RNA polymerase mediates Mycobacterium tuberculosis viability, rifampin resistance, and pathogenesis.

Authors:  Leslie A Weiss; Phillip G Harrison; Bryce E Nickels; Michael S Glickman; Elizabeth A Campbell; Seth A Darst; Christina L Stallings
Journal:  J Bacteriol       Date:  2012-08-17       Impact factor: 3.490

Review 6.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

7.  Molecular characterization of the eis promoter of Mycobacterium tuberculosis.

Authors:  Esteban A Roberts; Amanda Clark; Sarah McBeth; Richard L Friedman
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

8.  Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features.

Authors:  Cecilia Lindestam Arlehamn; Gregory Seumois; Anna Gerasimova; Charlie Huang; Zheng Fu; Xiaojing Yue; Alessandro Sette; Pandurangan Vijayanand; Bjoern Peters
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

9.  Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas.

Authors:  Smriti Mehra; Bapi Pahar; Noton K Dutta; Cecily N Conerly; Kathrine Philippi-Falkenstein; Xavier Alvarez; Deepak Kaushal
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

10.  Effect of vitamin D3 on phagocytic potential of macrophages with live Mycobacterium tuberculosis and lymphoproliferative response in pulmonary tuberculosis.

Authors:  G Chandra; P Selvaraj; M S Jawahar; V V Banurekha; P R Narayanan
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.